Engineered immune cells aim to trick the body into accepting a new kidney

NCT ID NCT04817774

Completed Disease control Sponsor: Sangamo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial tests a new cell therapy called TX200-TR101 in people who receive a kidney from a living donor. The therapy is made from the patient's own immune cells, which are genetically modified to help the body accept the donated kidney instead of rejecting it. The study focuses on safety and how well the therapy works, and involves a small group of participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TX200-TR101 (CAR-Tregs)
What this could lead to: If successful, this approach could reduce or eliminate the need for lifelong immunosuppressive drugs after kidney transplant, improving quality of life.
What could go wrong: This is an early-phase trial with a small number of participants. The therapy may not work as hoped, and there are risks from the cell infusion and genetic modification.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE KIDNEY TRANSPLANT REJECTION

Contacts and locations

Locations

Erasmus MC, University Medical Center

Rotterdam, 3015 CN, Netherlands
Leiden University Medical Centre

Leiden, 2333 ZA, Netherlands
Oxford University Hospitals NHS Foundation Trust,

Oxford, United Kingdom
University Hospitals Leuven

Leuven, Belgium
University Medical Center Groningen

Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.